Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.49 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7500993 | 1.00 | F3 (0.53) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL7501747 | 0.88 | KDM4E (0.51) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL7501752 | 0.88 | KDM4E (0.51) | F3MAPTKMT2ARAB9AMAOB | |
| SCHEMBL7501713 | 0.86 | CYP1B1 (0.50) | MAPTKMT2ARAB9AMAOBMEN1 | |
| SCHEMBL7503648 | 0.86 | SMN1; SMN2 (0.56) | MAPTMAOBMAOACYP1B1ALDH1A1 | |
| SCHEMBL3041751 | 0.86 | CXCL12 (0.40) | F3MAPTKMT2ARAB9ACYP3A4 | |
| SCHEMBL7503643 | 0.86 | SMN1; SMN2 (0.56) | MAPTMAOBMAOACYP1B1ALDH1A1 | |
| SCHEMBL7503829 | 0.86 | CYP1B1 (0.50) | MAPTRAB9AMAOBMAOACYP1B1 | |
| SCHEMBL3041754 | 0.86 | CXCL12 (0.40) | F3MAPTKMT2ARAB9ACYP3A4 | |
| SCHEMBL7503832 | 0.86 | CYP1B1 (0.50) | MAPTRAB9AMAOBMAOACYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344001-B2 | Azolylacryloyl derivatives as therapeutic agents for sickle cell disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344001-B2 | Azolylacryloyl derivatives as therapeutic agents for sickle cell disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180282287-A1 | AZOLYLACRYLOYL DERIVATIVES AS THERAPEUTIC AGENTS FOR SICKLE CELL DISEASE | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2018-10-04 | — | — | US | disclosed |
| EP-0924202-B1 | Imidazole derivative and medicine comprising the same as active ingredient | SSP CO LTD (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-6071943-A | IMMUNOMODULATORS WHICH SUPPRESS SPECIFIC CYTOKINES, FOR AUTOIMMUNE DISEASES | SSP CO. LTD. (JP) | 2000-06-06 | — | — | US | disclosed |
| EP-0924202-A1 | Imidazole derivative and medicine comprising the same as active ingredient | SSP Co., Ltd. (JP) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344001-B2 | Azolylacryloyl derivatives as therapeutic agents for sickle cell disease | HBG1, HIF1AN, TNNI3 | F3 1374/4885MAPT 2718/4885KMT2A 717/4885 |
| US-20180282287-A1 | AZOLYLACRYLOYL DERIVATIVES AS THERAPEUTIC AGENTS FOR SICKLE CELL DISEASE | HBG1, HIF1AN, TNNI3 | F3 1374/4885MAPT 2718/4885KMT2A 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.